Osimertinib-Induced Cardiotoxicity
نویسندگان
چکیده
منابع مشابه
Successful osimertinib rechallenge after osimertinib-induced pneumonitis in a patient with lung adenocarcinoma
Pneumonitis is a serious adverse event of EGFR-TKI treatment. Although several cases of EGFR-TKI rechallenge after EGFR-TKI-induced pneumonitis have been reported, little is known about post-pneumonitis osimertinib rechallenge. We describe a 69-year-old never-smoking Japanese woman with postoperative recurrent lung adenocarcinoma retreated with osimertinib after osimertinib-induced pneumonitis....
متن کاملSuccessful Osimertinib Rechallenge with Steroid Therapy after Osimertinib-induced Interstitial Lung Disease
A 62-year-old male with lung adenocarcinoma harboring an exon 19 deletion in the Epidermal growth factor receptor (EGFR) was treated with EGFR-tyrosine kinase inhibitors (TKIs) and several cytotoxic agents. After administering a fifth-line chemotherapy regimen, a liver biopsy revealed a diagnosis of recurrence with a T790M mutation. After an 82-day course of osimertinib therapy, the patient dev...
متن کاملTarget therapies-induced Cardiotoxicity
Target therapies have become an important component of the treatment of many cancers, with significant evidence of a gain in survival in their use, but at the same time, with increasing concern about their ability to cause a wide spectrum of secondary cardiovascular adverse events (left ventricular dysfunction, heart failure, hypertension, ischaemic heart disease, QT prolongation, sudden cardia...
متن کاملTrastuzumab-induced cardiotoxicity.
PURPOSE/OBJECTIVES To review trastuzumab-related cardiotoxic effects in the breast cancer adjuvant setting, present a system for pretreatment screening for cardiovascular risk factors, describe monitoring recommendations, provide a tool to facilitate adherence to monitoring guidelines, and discuss implications for patient education. DATA SOURCES Literature regarding cardiotoxicity and trastuz...
متن کاملDeconvoluting Kinase Inhibitor Induced Cardiotoxicity
Many drugs designed to inhibit kinases have their clinical utility limited by cardiotoxicity-related label warnings or prescribing restrictions. While this liability is widely recognized, designing safer kinase inhibitors (KI) requires knowledge of the causative kinase(s). Efforts to unravel the kinases have encountered pharmacology with nearly prohibitive complexity. At therapeutically relevan...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: JACC: CardioOncology
سال: 2019
ISSN: 2666-0873
DOI: 10.1016/j.jaccao.2019.10.006